Transplant Diagnostic Market Is Expected To Grow Rapidly Owing To Enhanced Demand In Medical Applications Till 2024: Grand View Research, Inc.

The global Transplant Diagnostic Market is expected to reach USD 895.2 million by 2024, according to a new report by Grand View Research Inc. The rising demand for organ transplantation is primarily fueling the demand for transplant diagnostics.
Constant healthcare research and development efforts are resulting in the introduction of technically advanced treatments, such as stem cell therapy and organ transplants. As a result, the adoption of these highly-advanced organ transplantation techniques is creating the demand for transplant diagnostics as they reduce the risk of infections and minimize the chances of an immune response through pre-operative assessments including histocompatibility tests, such as Human Leukocyte Antigen (HLA) typing, which determines donor-receiver organ or tissue compatibility prior to organ transplants.
In addition, pertinent organizations are supporting research and development initiatives in the field of organ transplant through grants and funding. As a result, innovative and advanced diagnostic tools are frequently entering into the market. On the other hand, high cost of the diagnostic tests is one of the major factors hindering the growth of the market.
Geographically, the market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa (MEA). North America and Europe together accounted for the largest market share in 2015. Developed economies and well-established healthcare infrastructure coupled with the presence of a highly developed research infrastructure are accelerating the adoption of organ and tissue transplant therapies in Europe and North America. As a consequence, the demand for transplant diagnostics is high in North America and Europe.
Wide adoption of HLA typing owing to its ability to determine organ compatibility between the donor and the receiver preceding organ transplants and to predict potential perioperative immunological complications is driving the growth of the molecular assay market in North America and Europe.
Asia Pacific is expected to show the fastest growth rate during the forecast period owing to the booming medical tourism in countries, such as India. Availability of advanced healthcare infrastructure and skilled professionals at alower costare anticipated to attract patients worldwide to this region for transplant procedures.
In addition, the presence of highly advanced healthcare infrastructure and the ongoing government initiatives to improve healthcare facilities in the country are collectively anticipated to boost the market growth in Japan during the forecast period. As a result, the Asia Pacific market is anticipated to reach USD 216.6 million in 2024.

View summary of this report @ http://www.grandviewresearch.com/industry-analysis/transplant-diagnostic-market

Further key findings from the study suggest:

·         The PCR-based molecular assay captured the largest share of the overall market in 2015. The large market share was mainly attributed to the extensive adoption of the PCR  technique in HLA typing.

·         The sequencing-based typing segment is anticipated to witness significant growth rate from 2016 to 2024. The escalation in the adoption of next generation sequencing (NGS) is the major factor expected to drive the growth of this segment during the forecast period.

·         The integration of sequencing with serological typing enhances diagnostic outcomes and, hence is expected to augment the growth of the sequencing segment during the forecast period

·         The reagents and consumables segment accounted for the largest market share in 2015. This large share is mainly attributed to the repeat purchase of these products.

·         North America captured the largest market share of around 38% in 2015 and is expected to maintain its dominance throughout the forecast period. Well-established research infrastructure, the increasing healthcare expenditure, high adoption rate ofthe advanced diagnostic techniques, and the growing R&D activities are some of the factors supporting the growth of the market in the region.

·         Asia Pacific is expected to witness significant growth during the forecast period owing to the expanding research opportunities, the increasing health care expenditure, and the rising awareness of organ donation in the region.

·         The booming medical tourism industry offers further growth opportunities for the market in Asia Pacific

·         Some major players in this market include Thermo Fisher Scientific, Inc., Illumina, Inc., F.Hoffmann La-Roche AG. Abbott Laboratories, Inc.,Qiagen N.V., Immucor Transplant Diagnostics, Inc., Bio-Rad Laboratories, Inc., Affymetrix, Inc.,  and Omixon Ltd. 

Read detailed report or request for sample of this research report: - http://www.grandviewresearch.com/industry-analysis/transplant-diagnostic-market/request

Grand View Research has segmented the Transplant Diagnostic Market on the basis of technology, product, and geography. 

Transplant Diagnostic Market by Technology, 2013 – 2024 (USD Million)      

• Molecular Assays
• PCR-Based Molecular Assays
• Sequencing-Based Molecular Assays
• Non-Molecular Assays
• Serological Assays
• Mixed Lymphocyte Culture (MLC) Assays

Transplant Diagnostic Market by Product, 2013 – 2024 (USD Million)       

• Reagents and Consumables 
• Instruments    
• Software and Services 

Transplant Diagnostics Market, by Region, 2013– 2024 (USD Million)

• North America
• U.S. Transplant Diagnostics Market by Product Type
• Canada Transplant Diagnostics Market by Product Type
• U.S.Transplant Diagnostics Market by Technology Type
• Canada Transplant Diagnostics Market by Technology
• Europe
• Germany Transplant Diagnostics Market by Product Type
• France Transplant Diagnostics Market by Product Type
• Germany Transplant Diagnostics Market by Technology
• France Transplant Diagnostics Market by Technology
• Asia Pacific
• China Transplant Diagnostics Market by Product Type
• India Transplant Diagnostics Market by Product Type
• China Transplant Diagnostics Market by Technology
• India Transplant Diagnostics Market by Technology
• Latin America
• Brazil Transplant Diagnostics Market by Product Type
• Mexico Transplant Diagnostics Market by Product Type
• Brazil Transplant Diagnostics Market by Technology
• Mexico Transplant Diagnostics Marketby Technology
• MEA
• South Africa Transplant Diagnostics Market by Product Type
• South Africa Transplant Diagnostics Market by Technology

Browse more reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/healthcare

Protein Labeling Market To Witness Growth On Account Of Rising Demand In Mass Spectroscopy And Protein Microarray Applications Till 2024

Global protein labeling market is anticipated  to reach USD 2,602.0 million by 2024, according to a new report by Grand View Research, Inc.Growing adoption of bioengineering technologies and rise in spending on R&D leading to a reduction in process complexity for protein labeling is expected to drive market growth.
Anticipatedlaunch & commercialization of novel products and ongoing improvement in techniques used for proteomic research is expected to further reinforce growth in demand. Improvements in accuracy, resolution and procedures used in techniques such as fluorescence&biorthogonaltagging are estimated to grow over the forecast period.
Ongoing development of genetic sequencing methodologies and consequent reduction in the cost of genome profiling is likely to drive demand for the next step of genetic analysis, i.e., protein expression analysis. Growth in a number of such protein profiling studies is expected to directly fuel demand for genomic and proteomic labeling techniques through to 2024.

View summary of this report @ http://www.grandviewresearch.com/industry-analysis/protein-labeling-market

Further key findings from the report suggest:

·         The reagents used for protein labeling accounted for the largest share of revenue in 2015. The larger share can be accounted for by the presence of high demand for labeling of peptides, antibodies and proteins at reaction locations of functional amino acids, and development of novel reagents that have chemo selective capabilities & amino acid cross linking abilities. 

·         Application of protein labeling in immunological techniques was observed to be responsible for generation of the largest share of revenue in 2015. Addition of nanoparticle-based tagging owing to ongoing R&D in emerged with the advent of nanoparticles and nanotechnology. Furthermore, aptamers-mediated nanoparticle-based peptide labeling method is gaining rapid acceptance for use in intracellular imaging and dynamic process tracking. 

·         Dye-based or fluorescence-based protein labeling have been observed to demonstrate high market adoption owing to associated usage in assays like ELISA, western blotting. Ongoing increase in the number of genetics-based R&D projects are also expected to boost market demand. 

·         On the basis of the experimental design, the market can be broadly categorized as in-vitro and in-vivo methodologies. A more minute analysis reveals that a further segment wise classification is also possible. Key segments from the sub-categorization are enzymatic &photo reactive tagging for the segments respectively. As enzymatic marking provides more flexibility of and has application in identification for a number of peptide profiling requirements, the segment is expected to witness lucrative growth over the forecast period.

·         North America accounted for over 45%of total revenue generated for 2015 owing to the presence of a very large installed base of genetic and proteomic profiling platforms across the U.S. High market usage of peptide identification techniques to be used in sequencing and expression analysis projects in a number of academic and clinical research institutes is another key factor responsible for the region’s large share. 

·         Key players operating in this industry include Thermo Fisher Scientific Inc., General Electric Healthcare Life Science, PerkinElmer Inc, Merck Millipore, Promega Corporation, LI-COR Inc., F. Hoffmann-La Roche AG, New England Biolabs, Eurogentec S.A., Kirkegaard & Perry Laboratories (KPL). 

Read detailed report or request for sample of this research report: - http://www.grandviewresearch.com/industry-analysis/protein-labeling-market/request

Grand View Research has segmented the global protein labeling market on the basis of product, application, method and region:
Global Protein Labeling Outlook, by Product (Revenue, USD Million, 2013 - 2024)

·         Reagents

·         Protein

·         Enzymes

·         Probes/ tags

·         Monoclonal antibodies

·         Other reagents

·         Kits

·         Services

Global Protein Labeling Outlook, by Application (Revenue, USD Million, 2013 - 2024)

·         Cell based-assay

·         Fluorescence microscopy

·         Immunological techniques

·         Mass spectrometry

• Protein micro assay

Global Protein Labeling Outlook, by Labeling Method (Revenue, USD Million, 2013 - 2024)

·         In vitro

·         Enzymatic labeling

·         Dye based labeling

·         Co translational labeling

·         Site specific labeling

·         Nano particle labeling

·         In vivo

·         Photo reactive labeling

·         Radioactive labeling

Protein Labeling Regional Outlook (Revenue, USD Million, 2013 - 2024)

·         North America

·         U.S.

·         Canada

·         Europe

·         Germany

·         UK

·         Asia Pacific

·         China

·         Japan

·         Latin America

·         Brazil

·         MEA

·         South Africa

Browse more reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/biotechnology

Fondaparinux Market Was Valued At USD 365.9 Million In 2015 And Is Expected To Witness A CAGR Of 7.8% From 2016 To 2024: Grand View Research, Inc.

The global fondaparinux market is expected to reach USD 686.3 million by 2024, according to a new report by Grand View Research, Inc. Fondaparinux is majorly used during knee and hip replacement surgeries. Arixtra, manufactured by GSK group of companies is the branded drug of Fondaparinux. The drug witnessed patent expiry in 2002. As the active molecule is highly complex to manufacture, it faced low generic competition until 2011. Generic manufacturer companies, such as Alchemia Ltd. and Apotex, Inc., received the Abbreviated New Drug Application approval in 2011 and instantly started the production of generic drugs.
Fondaparinux is used as an anticoagulant and shows improved survival compared with low-molecular-weight heparin. It is used for the prevention of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) and is administered subcutaneously. Moreover, Fondaparinux lowers the risk of ischemic events
The increasing collaboration between the key players for acquiring the Intellectual Property Rights (IPRs) in order to manufacture the molecule through patented technology is expected to drive growth. For instance, in July 2016 Dr. Reddy’s Laboratories Ltd. entered into an agreement with Alchemia Ltd. to purchase the IPRs of fondaparinux sodium for USD 17.5 million. In September 2014, Mylan N.V. purchased branded and generic versions of fondaparinux sodium from Aspen Global, Inc. for USD 225 million. The deal gave Mylan N.V. access to one of the two generics indicated for the treatment of PE.

View summary of this report @ http://www.grandviewresearch.com/industry-analysis/fondaparinux-market

Further key Findings From the Study Suggest:

·         Generics and authorized generics of Arixtra (fondaparinux sodium) dominated the market in 2015 with share of over 65.0%

·         The introduction of generic drugs in the market by Apotex, Inc., Dr. Reddy’s, and Mylan N.V. is expected to drive the market growth.

·         Branded drug Arixtra is however anticipated to witness declining growth rate majorly owing to patent expiration, high cost, and introduction of low-cost alternatives

·         North America held the largest market share of the global market in 2015. Key factors attributing to the dominance include constantly increasing geriatric population, rising prevalence of thrombosis, and the introduction of low-cost generics of Fondaparinux in the U.S.

·         In addition, the increasing number of awareness initiatives undertaken by government and nongovernment organizations for DVT and PE is driving the growth of the market in the North American region.

·         China’s huge population base with the rising disposable income coupled with the increased burden of chronic diseases is expected to be one of the major drivers for the Chinese market over the forecast period.

·         Moreover, the presence of local active pharmaceutical ingredients manufacturers and contract research organizations in China increased the number of foreign investments in the country. As a result, China is estimated to grow at CAGR of 21.2% till 2024

·         Major companies identified in the market include Dr. Reddy’s Laboratories, Inc., GSK group of companies, Mylan N.V., and Alchemia among others.

·         The Fondaparinux market is a consolidated market and is marked by the presence of mergers and acquisitions

Read detailed report or request for sample of this research report: - http://www.grandviewresearch.com/industry-analysis/fondaparinux-market/request

Grand View Research has segmented the Fondaparinux market on the basis of product and region:
Fondaparinux market, product outlook by revenue (USD Million, 2011 - 2024)

·         Branded

·         Generics

Fondaparinux market, product outlook by volume (thousand units, 2011 - 2024)

·         Branded

·         Generics

Fondaparinux market, regional outlook by revenue (USD Million, 2011 - 2024)

·         North America

·         Europe

·         Asia Pacific

·         China

·         RoW

Fondaparinux market, regional outlook by volume (thousand units, 2011 - 2024)

·         North America

·         Europe

·         Asia Pacific

·         China

·         RoW

Browse more reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/healthcare